CLINICAL TRIALS PROFILE FOR ELLENCE
✉ Email this page to a colleague
All Clinical Trials for ELLENCE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00066807 ↗ | Premenopausal Endocrine Responsive Chemotherapy Trial | Terminated | Breast International Group | Phase 3 | 2003-08-01 | The PERCHE trial evaluated the worth of adding adjuvant chemotherapy for premenopausal women with steroid hormone receptor positive early invasive breast cancer who receive ovarian function suppression plus either tamoxifen or exemestane for five years. The use of chemotherapy was determined by randomization. The method of ovarian function suppression (GnRH analogue for five years, surgical oophorectomy or ovarian irradiation) and the choice of tamoxifen or exemestane were determined by the investigator or by randomization in the IBCSG 25-02 TEXT trial [recommended option]. The trial was terminated early due to poor accrual. |
NCT00066807 ↗ | Premenopausal Endocrine Responsive Chemotherapy Trial | Terminated | National Cancer Institute (NCI) | Phase 3 | 2003-08-01 | The PERCHE trial evaluated the worth of adding adjuvant chemotherapy for premenopausal women with steroid hormone receptor positive early invasive breast cancer who receive ovarian function suppression plus either tamoxifen or exemestane for five years. The use of chemotherapy was determined by randomization. The method of ovarian function suppression (GnRH analogue for five years, surgical oophorectomy or ovarian irradiation) and the choice of tamoxifen or exemestane were determined by the investigator or by randomization in the IBCSG 25-02 TEXT trial [recommended option]. The trial was terminated early due to poor accrual. |
NCT00066807 ↗ | Premenopausal Endocrine Responsive Chemotherapy Trial | Terminated | International Breast Cancer Study Group | Phase 3 | 2003-08-01 | The PERCHE trial evaluated the worth of adding adjuvant chemotherapy for premenopausal women with steroid hormone receptor positive early invasive breast cancer who receive ovarian function suppression plus either tamoxifen or exemestane for five years. The use of chemotherapy was determined by randomization. The method of ovarian function suppression (GnRH analogue for five years, surgical oophorectomy or ovarian irradiation) and the choice of tamoxifen or exemestane were determined by the investigator or by randomization in the IBCSG 25-02 TEXT trial [recommended option]. The trial was terminated early due to poor accrual. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ELLENCE
Condition Name
Clinical Trial Locations for ELLENCE
Trials by Country
Clinical Trial Progress for ELLENCE
Clinical Trial Phase
Clinical Trial Sponsors for ELLENCE
Sponsor Name